TLP
Tri Locum Partners Portfolio holdings
AUM
$330M
This Quarter Return
+19.03%
1 Year Return
+35.44%
3 Year Return
+388.28%
5 Year Return
–
10 Year Return
–
AUM
$417M
AUM Growth
+$417M
(+5.5%)
Cap. Flow
-$9.03M
Cap. Flow
% of AUM
-2.16%
Top 10 Holdings %
Top 10 Hldgs %
79.89%
Holding
27
New
2
Increased
11
Reduced
6
Closed
7
Top Buys
| 1 |
Pfizer
PFE
|
$32.9M |
| 2 |
Stevanato
STVN
|
$26.1M |
| 3 |
Vaxcyte
PCVX
|
$18.1M |
| 4 |
VRNA
Verona Pharma
VRNA
|
$17.1M |
| 5 |
Natera
NTRA
|
$11M |
Top Sells
| 1 |
Ascendis Pharma
ASND
|
$31.1M |
| 2 |
Amgen
AMGN
|
$25.7M |
| 3 |
Axsome Therapeutics
AXSM
|
$19.3M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
$18.4M |
| 5 |
Insmed
INSM
|
$12.6M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Pfizer
PFE
$141B
| $50.2M | 12.01% | 1,732,935 +1,136,016 | +190% | +$32.9M |
|
2
Teva Pharmaceuticals
TEVA
$21.1B
| $49.7M | 11.9% | 2,755,737 +205,430 | +8% | +$3.7M |
|
|
3
Natera
NTRA
$23.1B
| $40.3M | 9.65% | 317,439 +86,854 | +38% | +$11M |
|
|
4
Stevanato
STVN
$6.28B
| $37.4M | 8.95% | 1,867,938 +1,302,516 | +230% | +$26.1M |
|
5
argenx
ARGX
$43.6B
| $33.9M | 8.11% | 62,474 -12,084 | -16% | -$6.55M |
|
6
Inspire Medical Systems
INSP
$2.77B
| $32M | 7.66% | 151,429 +18,153 | +14% | +$3.83M |
|
|
7
Vaxcyte
PCVX
$4B
| $31.1M | 7.44% | 271,922 +158,578 | +140% | +$18.1M |
|
|
AVDL
8
Avadel Pharmaceuticals
AVDL
$1.43B
| $21.8M | 5.22% | 1,660,955 +471,437 | +40% | +$6.18M |
|
9
United Therapeutics
UTHR
$13.8B
| $19.7M | 4.72% | 54,926 +4,826 | +10% | +$1.73M |
|
10
Legend Biotech
LEGN
$6.41B
| $17.7M | 4.23% | 362,270 +5,738 | +2% | +$280K |
|
|
VRNA
11
Verona Pharma
VRNA
$9.16B
| $17.1M | 4.09% | +593,980 | New | +$17.1M |
|
|
12
Insmed
INSM
$28.8B
| $10.5M | 2.52% | 143,920 -172,581 | -55% | -$12.6M |
|
13
Biohaven
BHVN
$1.63B
| $9.65M | 2.31% | +193,195 | New | +$9.65M |
|
14
Merus
MRUS
$4.98B
| $9.6M | 2.3% | 192,157 -143,357 | -43% | -$7.16M |
|
15
MindMed
MNMD
$676M
| $9.46M | 2.27% | 1,662,953 +1,280,898 | +335% | +$7.29M |
|
16
Madrigal Pharmaceuticals
MDGL
$9.76B
| $9.19M | 2.2% | 43,287 -22,065 | -34% | -$4.68M |
|
|
17
Axsome Therapeutics
AXSM
$6.05B
| $8.24M | 1.97% | 91,721 -214,792 | -70% | -$19.3M |
|
18
Novo Nordisk
NVO
$251B
| $8.01M | 1.92% | 67,257 +3,446 | +5% | +$410K |
|
19
Korro Bio
KRRO
$217M
| $2.14M | 0.51% | 64,014 -7,414 | -10% | -$248K |
|
20
Femasys
FEMY
$11.6M
| $34K | 0.01% | 30,606 | – | – |
|
21
Alnylam Pharmaceuticals
ALNY
$58.5B
| – | – | -45,000 | Closed | -$10.9M |
|
|
22
Amgen
AMGN
$155B
| – | – | -82,271 | Closed | -$25.7M |
|
|
23
Ascendis Pharma
ASND
$11.8B
| – | – | -227,762 | Closed | -$31.1M |
|
24
Ocular Therapeutix
OCUL
$2.12B
| – | – | -514,642 | Closed | -$3.52M |
|
25
Praxis Precision Medicines
PRAX
$958M
| – | – | -75,319 | Closed | -$3.12M |
|